Profile
David Howat worked as a Director of Preclinical Development at Nicox SA, a Chief Development Officer at Evgen Pharma Plc and Evgen Ltd., Head of Project Management at K.S.
Biomedix Holdings Plc, and a Team Leader at Celltech Chiroscience Plc.
Former positions of David Howat
| Companies | Position | End |
|---|---|---|
Evgen Ltd.
 Evgen Ltd. Medical/Nursing ServicesHealth Services Evgen Ltd. develops novel glucosinolate based products for the prevention and treatment of human disease. It engages in the clinical stage drug development that lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. Its activities also include carrying out preclinical work in multiple sclerosis and has a clinical interest in prostate cancer. The firm holds proprietary technology that enables sulforaphane to be synthesized and then subsequently stabilized for pharmaceutical application. The company was founded by Dr. Stephen Franklin on October 18, 2007 and is headquartered in Liverpool, the United Kingdom. | Director/Board Member | 2015-10-20 |
| THERACRYF PLC | Corporate Officer/Principal | - |
| K.S. Biomedix Holdings Plc | Corporate Officer/Principal | - |
| NICOX SA | Corporate Officer/Principal | - |
Celltech Chiroscience Plc
 Celltech Chiroscience Plc Miscellaneous Commercial ServicesCommercial Services Part of UCB SA, Celltech Chiroscience Plc is a research-based pharmaceutical group. | Corporate Officer/Principal | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| NICOX SA | Health Technology |
| THERACRYF PLC | Health Services |
| Private companies | 3 |
|---|---|
Celltech Chiroscience Plc
Celltech Chiroscience Plc Miscellaneous Commercial ServicesCommercial Services Part of UCB SA, Celltech Chiroscience Plc is a research-based pharmaceutical group. | Commercial Services |
Evgen Ltd.
Evgen Ltd. Medical/Nursing ServicesHealth Services Evgen Ltd. develops novel glucosinolate based products for the prevention and treatment of human disease. It engages in the clinical stage drug development that lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. Its activities also include carrying out preclinical work in multiple sclerosis and has a clinical interest in prostate cancer. The firm holds proprietary technology that enables sulforaphane to be synthesized and then subsequently stabilized for pharmaceutical application. The company was founded by Dr. Stephen Franklin on October 18, 2007 and is headquartered in Liverpool, the United Kingdom. | Health Services |
| K.S. Biomedix Holdings Plc | Health Technology |
- Stock Market
- Insiders
- David Howat
